循环肿瘤细胞与病理完全缓解:两项多中心II期试验(BEVERLY-1和-2)新辅助化疗联合贝伐珠单抗治疗炎性乳腺癌的汇总分析中的独立预后因素
该汇总分析纳入两项前瞻性II期试验中非转移性T4d炎性乳腺癌患者152例,评估新辅助化疗联合贝伐珠单抗治疗中循环肿瘤细胞(CTC)与循环内皮细胞(CEC)的预测和预后价值。基线CTC检出率为39%,治疗后降至9%;CTC或CEC水平与病理完全缓解率无相关性。基线CTC检出与更短的无病生存和总生存独立相关,基线无CTC且达到病理完全缓解的患者3年总生存率达94%。
要点
- 基线CTC检出率39%,4周期化疗后降至9%(P<0.01)。
- CTC或CEC水平与病理完全缓解率无相关性。
- 基线CTC检出(≥1 CTC/7.5 ml)与更短3年无病生存和总生存独立相关。
核心结论
- 在非转移性炎性乳腺癌中,CTC检出率为39%,对生存具有强且独立的预后价值。
- 新辅助治疗后病理完全缓解联合基线无CTC检出可识别总生存极佳(3年总生存率94%)的亚组,提示CTC计数或可纳入前瞻性试验的炎性乳腺癌分层。
研究设计与样本
- 两项前瞻性多中心II期试验(BEVERLY-1和BEVERLY-2)的汇总分析。
- 纳入非转移性T4d炎性乳腺癌患者152例,其中137例可评估CTC和CEC。
- BEVERLY-1:HER2阴性肿瘤,贝伐珠单抗联合序贯新辅助化疗(4周期FEC后4周期多西他赛)。
- BEVERLY-2:HER2阳性肿瘤,贝伐珠单抗联合多西他赛和曲妥珠单抗。
- CTC和CEC分别于7.5 ml和4 ml血液中采用CellSearch系统检测。
主要发现
- 2008年10月至2010年9月共纳入152例患者,137例可评估CTC和CEC。
- 基线55例患者可检出CTC(39%)。
- 4周期化疗后CTC检出率降至9%(P<0.01)。
- 病理完全缓解率为40%,CTC或CEC水平与病理完全缓解率无相关性。
- 中位随访43个月,基线CTC检出(≥1 CTC/7.5 ml)与更短3年无病生存相关(39% vs 70%,P<0.01,HR 2.80)和更短3年总生存相关(P<0.01)。
临床怎么用
- 原文结论提示CTC计数或可纳入前瞻性试验的炎性乳腺癌分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We present a pooled analysis of predictive and prognostic values of circulating tumour cells (CTC) and circulating endothelial cells (CEC) in two prospective trials of patients with inflammatory breast cancer (IBC) treated with neoadjuvant chemotherapy combined with neoadjuvant and adjuvant bevacizumab. PATIENTS AND METHODS: Nonmetastatic T4d patients were enrolled in two phase II multicentre trials, evaluating bevacizumab in combination with sequential neoadjuvant chemotherapy of four cycles of FEC followed by four cycles of docetaxel in HER2-negative tumour (BEVERLY-1) or docetaxel and trastuzumab in HER2-positive tumour (BEVERLY-2). CTC and CEC were detected in 7.5 and 4 ml of blood, respectively, with the CellSearch System. RESULTS: From October 2008 to September 2010, 152 patients were included and 137 were evaluable for CTC and CEC. At baseline, 55 patients had detectable CTC (39%). After four cycles of chemotherapy, a dramatic drop in CTC to a rate of 9% was observed (P < 0.01). Pathological complete response (pCR) rate was 40%. No correlation was found between CTC or CEC levels and pCR rate. Median follow-up was 43 months. CTC detection (≥1 CTC/7.5 ml) at baseline was associated with shorter 3-year disease-free survival (39% versus 70% for patients without CTC, P < 0.01, HR 2.80) and shorter 3-year overall survival (OS) (P < 0.01). In multivariate analysis, independent prognostic parameters for shorter survival were absence of hormonal receptors, no pCR and CTC detection at baseline. CEC level at baseline or variations during treatment had no prognostic value. CONCLUSION: In this pooled analysis of two prospective trials in nonmetastatic IBC, detection rate of CTC was 39% with a strong and independent prognostic value for survival. Combination of pCR after neoadjuvant treatment with no CTC detection at baseline isolated a subgroup of IBC with excellent OS (94% 3-year OS), suggesting that CTC count could be part of IBC stratification in prospective trials.
引用
- Pierga JY, Bidard FC, Autret A, et al. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. Ann Oncol. 2017. PMID: 28177480. doi:10.1093/annonc/mdw535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。